CEL-SCI Corp
Veridion Score
Composite trend over time
Why is CVM moving today?
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CVM.
CVM insider activity
CEL-SCI Corp
3 insiders bought in the last 90 days
Net buying: $998K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-06-30 | TALOR EYAL | Insider | buy | $1.04 | 2,307 | 9,318 | $2K | SEC Form 4 |
| 2026-07-01 | 2026-06-30 | PRICHEP PATRICIA B | Insider | buy | $1.04 | 4,125 | 17,489 | $4K | SEC Form 4 |
| 2026-07-01 | 2026-06-30 | KERSTEN GEERT R | Insider | buy | $1.04 | 5,192 | 216,142 | $5K | SEC Form 4 |
| 2026-05-18 | 2026-05-14 | KERSTEN GEERT R | Insider | buy | $1.20 | 300,000 | 311,547 | $360K | SEC Form 4 |
| 2026-05-14 | 2026-05-13 | KERSTEN GEERT R | Insider | buy | $1.19 | 100,000 | 222,497 | $119K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 19 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moCVM contract awards, year to date.
Public federal awards linked to this ticker.
CVM lobbying filings, year to date.
Registered lobbying filings matched to CEL-SCI Corp.